Condition
Severe Adverse Reactions
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Unknown2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04479553Unknown
Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.
NCT03640884Unknown
Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study
NCT02239237Completed
Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
Showing all 3 trials